Table 2.

Adverse events reported during the study

Events	GC + IM group (n = 41)	GC + IM + HCQ group (n = 31)
	n (%)
Number of events
0	27 (66)	26 (84)
1	13 (32)	4 (13)
≥2	1 (2)	1 (3)
Upper respiratory infection	1 (2)	0
Pneumonia	2 (5)	0
Urinary tract infection	3 (7)	1 (3)
Lymphopenia	2 (5)	0
Glucose intolerance	1 (2)	0
Hepatic enzymes increased	2 (5)	2 (6)
Thrombocytopenia	1 (2)	0
Rash	1 (2)	2 (6)
Nausea	1 (2)	0
Fecal occult blood	1 (2)	1 (3)
Visual field defect	0	1 (3)

GC, glucocorticoid; HCQ, hydroxychloroquine; IM, immunosuppressant.